| |
| | Drug Delivery Technology - Article Index |
 | | And for good reason, because adhesive transdermal patches, which utilize passive diffusion of drugs across the skin as the delivery mechanism, have been available on the US market for more than 20 years to treat systemic illnesses, and are the predominant transdermal drug delivery (TDD) technology that has been approved by the FDA. |
 | | For passive drug-in-adhesive (DIA) transdermal patches, the workhorse of current transdermal technologies, the formulation tends to be a major focus of research because it is a challenge to integrate adhesive, drug(s), and excipient(s) into a single, simple, elegant system and achieve product stability and optimal system performance throughout the duration of the wear period. |
 | | A new area of intense transdermal research and development is the development of devices that create micropores in the stratum corneum, the topmost layer of the skin that serves as the greatest barrier to drug diffusion. |
| www.drugdeliverytech.com /cgi-bin/articles.cgi?idArticle=143 (3379 words) |
|